We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current RXRX market cap is 2.34B. The company's latest EPS is USD -1.3981 and P/E is -7.12.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 13.16M | 13.68M | 12.13M | 11.02M | 10.53M |
Operating Income | -62.57M | -60.98M | -69.87M | -81.72M | -99.55M |
Net Income | -60.45M | -57.49M | -65.33M | -76.73M | -93.02M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 2.32M | 3.96M | 10.18M | 39.84M | 44.58M |
Operating Income | -62.44M | -84.38M | -182.78M | -245.73M | -350.06M |
Net Income | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 611.53M | 701.29M | 627.37M | 666.7M | 630.83M |
Total Liabilities | 223.5M | 215.48M | 197.19M | 197.74M | 192.86M |
Total Equity | 388.03M | 485.81M | 430.18M | 468.96M | 437.97M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 101.43M | 298.59M | 610.35M | 701.29M | 653.7M |
Total Liabilities | 24.59M | 56.56M | 67.41M | 215.48M | 190.26M |
Total Equity | -124.27M | -206.29M | 542.94M | 485.81M | 463.44M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -38.78M | -83.52M | -73.32M | -140.78M | -213.7M |
Investing | 201.23M | 193.25M | -5.34M | -7.39M | -7.74M |
Financing | 7.09M | 154.35M | 1.92M | 5.71M | 59.47M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -57.04M | -45.4M | -158.61M | -83.52M | -287.78M |
Investing | -3.91M | -8.74M | -271.74M | 193.25M | -10.23M |
Financing | 120.41M | 246.14M | 458.54M | 154.35M | 140.13M |
Market Cap | 2.34B |
Price to Earnings Ratio | -7.12 |
Price to Sales Ratio | 52.37 |
Price to Cash Ratio | 5.96 |
Price to Book Ratio | 5.04 |
Dividend Yield | - |
Shares Outstanding | 234.65M |
Average Volume (1 week) | 4.92M |
Average Volume (1 Month) | 6.68M |
52 Week Change | 48.66% |
52 Week High | 16.745 |
52 Week Low | 4.54 |
Spread (Intraday) | 0.01 (0.1%) |
Company Name | Recursion Pharmaceuticals Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.recursion.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions